The first TKI approved by Food and Drug Administration (FDA) for use in CML patients was imatinib in 2001, which inhibits constitutive tyrosine kinase activity and returns BCR::ABL1 to its inactive conformation by binding tightly to its ATP binding site. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.